An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome

S. Kojima, M. Sako, K. Kato, G. Hosoi, T. Sato, A. Ohara, K. Koike, Y. Okimoto, S. Nishimura, Y. Akiyama, Tetsushi Yoshikawa, E. Ishii, J. Okamura, M. Yazaki, Y. Hayashi, M. Eguchi, I. Tsukimoto, K. Ueda

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

In recent pediatric collaborative studies of acute myeloid leukemia (AML), patients with Down's syndrome (DS) have better outcome than other patients when they were treated according to their intensive AML protocols. This may be attributed to enhanced sensitivity of DS AML cells to selected chemotherapeutic agents. We evaluated a less intensive chemotherapeutic regimen which was specifically designed for children with AML-DS. Remission induction chemotherapy consisted of daunorubicin (25 mg/m2/day for 2 days), cytosine arabinoside (100 mg/m2/day for 7 days), and etoposide (150 mg/m2/day for 3 days). Patients received one to seven courses of consolidation therapy of the same regimen. Thirty-three patients were enrolled on the study and their clinical, hematologic and immunophenotypic features were analyzed. Of the 33 patients, all were younger than 4 years and diagnnsed as having acute megakaryoblastic leukemia or myelodysplastic syndrome. All patients achieved a complete remission and estimated 8 year event-free survival rate was 80 ± 7%. Three patients relapsed and two died due to cardiac toxicity and one due to septic shock. The results of our study showed that patients with AML-DS constitute a unique biologic subgroup and should be treated according to a less intensive protocol designed for AML-DS.

Original languageEnglish
Pages (from-to)786-791
Number of pages6
JournalLeukemia
Volume14
Issue number5
DOIs
Publication statusPublished - 01-01-2000

Fingerprint

Myelodysplastic Syndromes
Down Syndrome
Acute Myeloid Leukemia
Leukemia, Megakaryoblastic, Acute
Remission Induction
Induction Chemotherapy
Daunorubicin
Cytarabine
Etoposide
Myeloid Cells
Septic Shock
Disease-Free Survival
Survival Rate
Pediatrics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kojima, S. ; Sako, M. ; Kato, K. ; Hosoi, G. ; Sato, T. ; Ohara, A. ; Koike, K. ; Okimoto, Y. ; Nishimura, S. ; Akiyama, Y. ; Yoshikawa, Tetsushi ; Ishii, E. ; Okamura, J. ; Yazaki, M. ; Hayashi, Y. ; Eguchi, M. ; Tsukimoto, I. ; Ueda, K. / An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. In: Leukemia. 2000 ; Vol. 14, No. 5. pp. 786-791.
@article{7585587e70f54b1c8a327c5dde33baa7,
title = "An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome",
abstract = "In recent pediatric collaborative studies of acute myeloid leukemia (AML), patients with Down's syndrome (DS) have better outcome than other patients when they were treated according to their intensive AML protocols. This may be attributed to enhanced sensitivity of DS AML cells to selected chemotherapeutic agents. We evaluated a less intensive chemotherapeutic regimen which was specifically designed for children with AML-DS. Remission induction chemotherapy consisted of daunorubicin (25 mg/m2/day for 2 days), cytosine arabinoside (100 mg/m2/day for 7 days), and etoposide (150 mg/m2/day for 3 days). Patients received one to seven courses of consolidation therapy of the same regimen. Thirty-three patients were enrolled on the study and their clinical, hematologic and immunophenotypic features were analyzed. Of the 33 patients, all were younger than 4 years and diagnnsed as having acute megakaryoblastic leukemia or myelodysplastic syndrome. All patients achieved a complete remission and estimated 8 year event-free survival rate was 80 ± 7{\%}. Three patients relapsed and two died due to cardiac toxicity and one due to septic shock. The results of our study showed that patients with AML-DS constitute a unique biologic subgroup and should be treated according to a less intensive protocol designed for AML-DS.",
author = "S. Kojima and M. Sako and K. Kato and G. Hosoi and T. Sato and A. Ohara and K. Koike and Y. Okimoto and S. Nishimura and Y. Akiyama and Tetsushi Yoshikawa and E. Ishii and J. Okamura and M. Yazaki and Y. Hayashi and M. Eguchi and I. Tsukimoto and K. Ueda",
year = "2000",
month = "1",
day = "1",
doi = "10.1038/sj.leu.2401754",
language = "English",
volume = "14",
pages = "786--791",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

Kojima, S, Sako, M, Kato, K, Hosoi, G, Sato, T, Ohara, A, Koike, K, Okimoto, Y, Nishimura, S, Akiyama, Y, Yoshikawa, T, Ishii, E, Okamura, J, Yazaki, M, Hayashi, Y, Eguchi, M, Tsukimoto, I & Ueda, K 2000, 'An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome', Leukemia, vol. 14, no. 5, pp. 786-791. https://doi.org/10.1038/sj.leu.2401754

An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. / Kojima, S.; Sako, M.; Kato, K.; Hosoi, G.; Sato, T.; Ohara, A.; Koike, K.; Okimoto, Y.; Nishimura, S.; Akiyama, Y.; Yoshikawa, Tetsushi; Ishii, E.; Okamura, J.; Yazaki, M.; Hayashi, Y.; Eguchi, M.; Tsukimoto, I.; Ueda, K.

In: Leukemia, Vol. 14, No. 5, 01.01.2000, p. 786-791.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome

AU - Kojima, S.

AU - Sako, M.

AU - Kato, K.

AU - Hosoi, G.

AU - Sato, T.

AU - Ohara, A.

AU - Koike, K.

AU - Okimoto, Y.

AU - Nishimura, S.

AU - Akiyama, Y.

AU - Yoshikawa, Tetsushi

AU - Ishii, E.

AU - Okamura, J.

AU - Yazaki, M.

AU - Hayashi, Y.

AU - Eguchi, M.

AU - Tsukimoto, I.

AU - Ueda, K.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - In recent pediatric collaborative studies of acute myeloid leukemia (AML), patients with Down's syndrome (DS) have better outcome than other patients when they were treated according to their intensive AML protocols. This may be attributed to enhanced sensitivity of DS AML cells to selected chemotherapeutic agents. We evaluated a less intensive chemotherapeutic regimen which was specifically designed for children with AML-DS. Remission induction chemotherapy consisted of daunorubicin (25 mg/m2/day for 2 days), cytosine arabinoside (100 mg/m2/day for 7 days), and etoposide (150 mg/m2/day for 3 days). Patients received one to seven courses of consolidation therapy of the same regimen. Thirty-three patients were enrolled on the study and their clinical, hematologic and immunophenotypic features were analyzed. Of the 33 patients, all were younger than 4 years and diagnnsed as having acute megakaryoblastic leukemia or myelodysplastic syndrome. All patients achieved a complete remission and estimated 8 year event-free survival rate was 80 ± 7%. Three patients relapsed and two died due to cardiac toxicity and one due to septic shock. The results of our study showed that patients with AML-DS constitute a unique biologic subgroup and should be treated according to a less intensive protocol designed for AML-DS.

AB - In recent pediatric collaborative studies of acute myeloid leukemia (AML), patients with Down's syndrome (DS) have better outcome than other patients when they were treated according to their intensive AML protocols. This may be attributed to enhanced sensitivity of DS AML cells to selected chemotherapeutic agents. We evaluated a less intensive chemotherapeutic regimen which was specifically designed for children with AML-DS. Remission induction chemotherapy consisted of daunorubicin (25 mg/m2/day for 2 days), cytosine arabinoside (100 mg/m2/day for 7 days), and etoposide (150 mg/m2/day for 3 days). Patients received one to seven courses of consolidation therapy of the same regimen. Thirty-three patients were enrolled on the study and their clinical, hematologic and immunophenotypic features were analyzed. Of the 33 patients, all were younger than 4 years and diagnnsed as having acute megakaryoblastic leukemia or myelodysplastic syndrome. All patients achieved a complete remission and estimated 8 year event-free survival rate was 80 ± 7%. Three patients relapsed and two died due to cardiac toxicity and one due to septic shock. The results of our study showed that patients with AML-DS constitute a unique biologic subgroup and should be treated according to a less intensive protocol designed for AML-DS.

UR - http://www.scopus.com/inward/record.url?scp=0034094596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034094596&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2401754

DO - 10.1038/sj.leu.2401754

M3 - Article

C2 - 10803507

AN - SCOPUS:0034094596

VL - 14

SP - 786

EP - 791

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -